Graphs of marginal mean values of the studied parameters for dolphin kick, flutter kick and breaststroke kick with and without diving gear (Parameters that were not statistically d... حسب Marek Rejman (9199616)

Decreases in locomotor responses to a single METH injection in <i>Ptprz</i>-KO mice. حسب Akihiro Fujikawa (122649)

PI+ total immune cells are decreased at days 2, 5, and 14 following IR, and PI+ neutrophils are increased at day 30. حسب Jordan A. Gunning (18143970)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. حسب Rodrigo Ibarra-García-Padilla (19697623)

Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data حسب E.J. Martins (7141313)

"…MMC (n=10) and healthy (n=25) participants of both genders with a mean age of 12.45 years (SD=2.1) were assessed for weight, height, respiratory performance, and isometric peak for shoulder flexors, extensors, abductors, and adductors, using an isokinetic dynamometer. …"

Graphs showing the mean temperature increase at the positions with the highest mean temperature increase for the MIPS (A) and MONO (B) systems and three drilling protocols (DP1, DP... حسب Marsel Ganeyev (21453399)

Depletion of EphA3 or EphA4 recovers the decreased ERK and Akt activation and lytic gene expression in RNF5 KO PEL cells. حسب Xiaojuan Li (351842)

TPP decreases melanoma tumor growth rate when administered via hydrogel. حسب Kyle C. Kloepping (9928265)

Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. حسب Régis Cohen (11419436)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات: